Drugs for HER-2-positive Breast Cancer

Edited by Sibilia, Maria; Edited by Zielinski, Christoph C.; Edited by Bartsch, Rupert; Edited by Grunt, Thomas

Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.

「Nielsen BookData」より

[目次]

  • Drugs for HER-2-positive Breast Cancer: A Major Approval for Translational Cancer Research (Maria Sibilia, Christoph C. Zielinski, Rupert Bartsch, Thomas Grunt).- The EGFR/ErbB family in breast cancer: from signaling to therapy (Wolfgang J. Kostler and Yosef Yarden).- Trastuzumab as Adjuvant treatment for early stage HER-2 positive breast cancer (Rupert Bartsch and Guenther G. Steger).- Trastuzumab Resistance in breast cancer (Floriana Morgillo, Michele Orditura, Teresa Troiani, Erika Martinelli, Ferdinando De Vita, Fortunato Ciardiello).- Treatment with Trastuzumab beyond Progression (Gunter von Minckwitz and Cristina Pirvulescu).- Pertuzumab - a HER-2 dimerisation inhibitor - for the treatment of breast and other cancers (Giulia Bianchi and Luca Gianni).- Beyond trastuzumab: Second generation targeted therapies for HER-2-positive breast cancer (Flavio F. Solca, Guenther R. Adolf, Hilary Jones, Martina M. Uttenreuther-Fischer).

「Nielsen BookData」より

この本の情報

書名 Drugs for HER-2-positive Breast Cancer
著作者等 Bartsch, Rupert
Grunt, Thomas
Zielinski, Christoph C.
Sibilia, Maria
シリーズ名 Milestones in Drug Therapy
出版元 Springer Basel
刊行年月 2013.02.24
ページ数 120p
大きさ H235 x W155
ISBN 9783034803182
言語 英語
出版国 スイス
この本を: 
このエントリーをはてなブックマークに追加

Yahoo!ブックマークに登録
この記事をクリップ!
Clip to Evernote
このページを印刷

外部サイトで検索

この本と繋がる本を検索

ウィキペディアから連想